11:17 AM EST, 12/23/2024 (MT Newswires) -- Psyence Biomedical ( PBM ) said Monday it received a Nasdaq notification that the firm has regained compliance with all applicable Nasdaq listing requirements, including minimum market value and stockholders' equity requirement.

"With Nasdaq compliance, a debt free balance sheet and a cash position of $5.6 million, the company is well positioned to execute its business plan and clinical trial, for which patient screening has commenced," Psyence said.

Price: 2.37, Change: -0.81, Percent Change: -25.47